Overcoming Neoantigen Screening Bottlenecks & Empowering Neoantigen Predictions for Expansion of Neoantigen Reactive TILs
Time: 1:05 pm
day: Pre-Conference Workshop Day
Details:
Many TIL developers face bottlenecks in screening for neoantigens and predicting immunogenicity and selectivity potential of discovered neoantigens, which exasperates manufacturing timelines. This workshop discusses solutions and current advancements to expedite processes, crucial for advancing TIL therapy development amidst burgeoning demand.
Join this workshop to:
- Discuss the challenge of intratumor heterogeneity and tools for targeting clonal neoantigens which are present on every tumour cell
- Explore state-of-the-art bioinformatics tools to accelerate isolation of potentially immunogenic neoantigens
- Evaluate tools to screen for challenging antigens such as MHC class 2 neoantigens
- Dive deep into the development of assays for predicting the selectivity and immunogenicity of neoantigens, including assay design and validation methodologies
- Engage in technical discussions on the challenges and limitations associated with current approaches in neoantigen screening and prediction
- Consider the ability to overcome immune evasion mechanisms through neoantigen selection
